Brigade-M3 European Acquisition Corp. Redemption notice
25.5.2023 18:30:00 EEST | Business Wire | Press release
Brigade-M3 European Acquisition Corp. (the "Company"), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V. ("Euronext Amsterdam"), today announces that it will not conclude a business combination before its business combination deadline on 14 June 2023 (the "Business Combination Deadline"). Therefore, the board of directors of the Company (the "Board") resolved to initiate the redemption of all listed unit shares and ordinary shares in the share capital of Company (the "Units" and "Ordinary Shares", respectively) following the Business Combination Deadline in accordance with the terms and conditions for the redemption of the Units and Ordinary Shares in the Company's articles of association and as disclosed in the Company's IPO prospectus dated 8 December 2021 (the "Prospectus").
Since the Company became listed on Euronext Amsterdam on 14 December 2021, the Company has been searching for a target to consummate a business combination. During this period, the Company has investigated various potential targets and held explorative talks with a selection of them, but despite extensive efforts to date, the Company has not been able to find a suitable target for a business combination. As the Business Combination Deadline is forthcoming, the Board deems it highly unlikely that the Company will be able to complete a business combination before the Business Combination Deadline and, therefore, the Board has decided to initiate the redemption of the Units and Ordinary Shares following the Business Combination Deadline. In accordance with the disclosure in the Prospectus, the Company will procure that the amount held in the Escrow Account will be returned to the holders of Units and Ordinary Shares as promptly as reasonably possible but not more than ten trading days after the Business Combination Deadline.
Holders of Units and Ordinary Shares will receive redemption proceeds from the Escrow Account through payment by the Company's Listing Agent, at an expected price per Unit or Ordinary Share of $10.20 plus accrued interest (this amount comprises of (i) $10.00 initial subscription price; (ii) $0.20 escrow overfunding by the Company's sponsor; and (iii) the pro rata part of the accrued interest on the Escrow Account). Holders of Units and Ordinary Shares will receive this payment in exchange for the delivery of the Units or Ordinary Shares via the shareholder’s intermediary to the Listing Agent. As a result of the Company not completing a business combination before the Business Combination Deadline, the public warrants and the sponsor warrants will automatically expire without value on the Business Combination Deadline in line with the terms and conditions of the warrants and the disclosure in the Prospectus. There will be no distribution of proceeds or otherwise from the Escrow Account with respect to the public warrants or the sponsor warrants.
Indicative timetable
The timetable below sets forth certain expected key dates for the redemption of the Units and Ordinary Shares.
|
Event |
Date |
||
|
Business Combination Deadline |
14 June 2023 |
||
|
Last trading day |
14 June 2023 |
||
|
Expiration of sponsor warrants and public warrants |
15 June 2023 |
||
|
Record date for the redemption of Units and Ordinary Shares |
16 June 2023 |
||
|
Payment of redemption proceeds |
20 June 2023 |
||
|
Redemption of Units and Ordinary Shares |
21 June 2023 |
Post-Redemption
Following the Business Combination Deadline and the redemption of the Units and Ordinary Shares (and the expiration of the public warrants and the sponsor warrants), the only outstanding securities of the Company will be the sponsor shares. The Board intends to seek sponsor shareholder approval to adopt amended and restated memorandum and articles of association in order to facilitate the re-purposing and continuation of the Company, subject to additional capital being committed by the sponsor for such purpose. The redeemed Units and Ordinary Shares will be held in treasury by the Company for the purpose of re-allocating such Units and Ordinary Shares in the future.
IMPORTANT INFORMATION
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
DISCLAIMER
This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does not contain or constitute an offer of securities for sale or an invitation or offer to the public for securities in any jurisdiction.
In the EEA, this announcement is only directed at persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU 2017/1129) as amended. In the United Kingdom, this announcement is directed only at “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation (EU) No 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005640/en/
Contact information
ENQUIRIES
Brigade-M3 European Acquisition Corp.
c/o Brigade Capital Management, LP
399 Park Avenue, 16th Floor
New York, NY 10022
Email: BrigadeM3EAC@brigadecapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
